Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference
VolitionRx (NYSE AMERICAN: VNRX) has announced its participation in the 97th Annual Western Veterinary Conference (WVC), scheduled for March 2-5, 2025, in Las Vegas. The conference, attracting approximately 20,000 veterinary professionals, will feature presentations about the company's Nu.Q® Vet Cancer Test.
The company will host three presentations by notable veterinary professionals: Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes, and Dr. Tom Butera. These sessions will focus on various aspects of the Nu.Q® Vet Cancer Test, including cancer journey navigation, practical implementation, and early detection screening. The test is designed to detect seven common cancers in dogs and is marketed as accessible, affordable, and easy-to-use with rapid results.
VolitionRx (NYSE AMERICAN: VNRX) ha annunciato la sua partecipazione al 97° Congresso Annuale della Conferenza Veterinaria Occidentale (WVC), previsto per il 2-5 marzo 2025 a Las Vegas. La conferenza, che attirerà circa 20.000 professionisti veterinari, presenterà relazioni sul Nu.Q® Vet Cancer Test dell'azienda.
L'azienda ospiterà tre presentazioni da parte di noti professionisti veterinari: Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes e Dr. Tom Butera. Queste sessioni si concentreranno su vari aspetti del Nu.Q® Vet Cancer Test, inclusa la navigazione nel percorso oncologico, l'implementazione pratica e lo screening per la rilevazione precoce. Il test è progettato per rilevare sette tipi comuni di cancro nei cani ed è commercializzato come accessibile, conveniente e facile da usare con risultati rapidi.
VolitionRx (NYSE AMERICAN: VNRX) ha anunciado su participación en la 97ª Conferencia Veterinaria Occidental (WVC), programada del 2 al 5 de marzo de 2025 en Las Vegas. La conferencia, que atraerá a aproximadamente 20,000 profesionales veterinarios, contará con presentaciones sobre el Nu.Q® Vet Cancer Test de la compañía.
La empresa organizará tres presentaciones a cargo de destacados profesionales veterinarios: Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes y Dr. Tom Butera. Estas sesiones se centrarán en varios aspectos del Nu.Q® Vet Cancer Test, incluyendo la navegación en el viaje del cáncer, la implementación práctica y la detección temprana. El test está diseñado para detectar siete tipos comunes de cáncer en perros y se comercializa como accesible, asequible y fácil de usar, con resultados rápidos.
VolitionRx (NYSE AMERICAN: VNRX)는 2025년 3월 2일부터 5일까지 라스베가스에서 열리는 제97회 서부 수의학 회의(WVC)에 참가한다고 발표했습니다. 약 20,000명의 수의학 전문인들이 참석하는 이 회의에서는 회사의 Nu.Q® Vet Cancer Test에 대한 발표가 있을 예정입니다.
회사는 저명한 수의학 전문가인 Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes, Dr. Tom Butera의 세 가지 발표를 주최할 것입니다. 이 세션은 Nu.Q® Vet Cancer Test의 다양한 측면, 즉 암 여정 탐색, 실용적인 구현 및 조기 발견 스크리닝에 초점을 맞출 것입니다. 이 테스트는 개에서 흔히 발생하는 일곱 가지 암을 탐지하도록 설계되었으며, 접근 가능하고, 저렴하며, 사용하기 쉽고 빠른 결과를 제공합니다.
VolitionRx (NYSE AMERICAN: VNRX) a annoncé sa participation à la 97e Conférence Annuelle de Médecine Vétérinaire de l'Ouest (WVC), prévue du 2 au 5 mars 2025 à Las Vegas. La conférence, qui attirera environ 20 000 professionnels vétérinaires, présentera des exposés sur le Nu.Q® Vet Cancer Test de l'entreprise.
L'entreprise accueillera trois présentations de professionnels vétérinaires de renom : Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes et Dr. Tom Butera. Ces sessions porteront sur divers aspects du Nu.Q® Vet Cancer Test, y compris la navigation dans le parcours du cancer, la mise en œuvre pratique et le dépistage précoce. Le test est conçu pour détecter sept cancers courants chez les chiens et est commercialisé comme accessible, abordable et facile à utiliser avec des résultats rapides.
VolitionRx (NYSE AMERICAN: VNRX) hat seine Teilnahme an der 97. jährlichen Western Veterinary Conference (WVC) angekündigt, die vom 2. bis 5. März 2025 in Las Vegas stattfinden wird. Die Konferenz, die etwa 20.000 Veterinärfachleute anzieht, wird Präsentationen über den Nu.Q® Vet Cancer Test des Unternehmens beinhalten.
Das Unternehmen wird drei Präsentationen von namhaften Veterinärmedizinern veranstalten: Dr. Sue Ettinger (Dr. Sue Cancer Vet), Dr. Brett Cordes und Dr. Tom Butera. Diese Sitzungen werden sich auf verschiedene Aspekte des Nu.Q® Vet Cancer Test konzentrieren, einschließlich der Navigation im Krebsverlauf, praktischer Umsetzung und Früherkennungsscreening. Der Test ist darauf ausgelegt, sieben häufige Krebsarten bei Hunden zu erkennen und wird als zugänglich, erschwinglich und einfach zu bedienen mit schnellen Ergebnissen vermarktet.
- Strategic expansion of Nu.Q® Vet Cancer Test awareness in North American market
- Product capable of detecting 7 common canine cancers
- Large market exposure through 20,000 veterinary professionals at WVC
- None.
Volition will showcase presentations from Dr. Sue Ettinger, aka Dr. Sue Cancer Vet, Dr. Brett Cordes, DVM, and Dr. Tom Butera, DVM
Representatives will also be available at exhibition booth #2943
In addition, the Volition team is hosting a meet and greet at exhibition booth #2943 showcasing the Company's Nu.Q® Vet Cancer Test.
Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC commented:
"We are delighted to showcase the Nu.Q® Vet Cancer Test to the veterinary community attending WVC this year. We continue our strategic commercialization efforts in
Featured Volition Events
Presentation 1
Date and Time: Monday, March 3, 2025, from 2:00PM - 2:50 PM
Topic: "Detect, Treat, Monitor: Navigating the Canine Cancer Journey with Nu.Q® Vet Cancer Test"
Speaker: Dr. Sue Ettinger, DVM, DACVIM (Oncology). Dr. Ettinger is known throughout the veterinary community as "Dr. Sue Cancer Vet."
Location: Ballroom F, Level 2
Presentation 2
Date and Time: Tuesday, March 4, 2025, from 10:30 AM - 11:00 AM
Topic: "Utilizing the Nu.Q® Vet Cancer Test in Practice"
Speaker: Dr. Brett Cordes, DVM
Location: Western Frontier, Learning Hub, Exhibit Hall Level 1
Presentation 3
Date and Time: Wednesday, March 5 from 12:10 PM -1:00 PM
Topic: "The Nu.Q® Vet Cancer Test - Early Detection with Canine Cancer Screening"
Speaker: Dr. Tom Butera, DVM
Location: Ballroom J, Level 2
About WVC
The WVC Annual Conference is one of the largest and longest-running veterinary conferences in the country. WVC offers hundreds of educational opportunities, including lectures, hands-on CE labs, and drop-in learning sessions.
The conference will take place this year at the Mandalay Bay Convention Center in
About Volition
Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-showcases-nuq-vet-cancer-test-at-the-97th-wvc-annual-conference-302387815.html
SOURCE VolitionRx Limited
FAQ
What is the Nu.Q® Vet Cancer Test showcased by VNRX at WVC 2025?
When and where is VNRX presenting at the Western Veterinary Conference 2025?
Who are the key speakers presenting VNRX's Nu.Q® Vet Cancer Test at WVC 2025?
What is the significance of VNRX's presence at the 2025 WVC conference?
